REGENXBIO Inc. (NASDAQ:RGNX) Shares Bought by DnB Asset Management AS

DnB Asset Management AS increased its position in REGENXBIO Inc. (NASDAQ:RGNX) by 20.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,539 shares of the biotechnology company’s stock after buying an additional 2,434 shares during the period. DnB Asset Management AS’s holdings in REGENXBIO were worth $112,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Redmile Group LLC raised its holdings in REGENXBIO by 7.1% in the 3rd quarter. Redmile Group LLC now owns 4,892,902 shares of the biotechnology company’s stock valued at $51,327,000 after acquiring an additional 323,100 shares during the last quarter. JPMorgan Chase & Co. increased its stake in REGENXBIO by 67.0% in the fourth quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company’s stock valued at $31,975,000 after purchasing an additional 1,659,206 shares during the last quarter. Geode Capital Management LLC lifted its position in REGENXBIO by 4.2% during the third quarter. Geode Capital Management LLC now owns 1,088,651 shares of the biotechnology company’s stock worth $11,422,000 after buying an additional 44,037 shares during the period. Assenagon Asset Management S.A. boosted its stake in REGENXBIO by 53.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company’s stock worth $6,621,000 after buying an additional 296,700 shares during the last quarter. Finally, Norges Bank purchased a new stake in REGENXBIO in the 4th quarter valued at about $3,474,000. Hedge funds and other institutional investors own 88.08% of the company’s stock.

Wall Street Analysts Forecast Growth

RGNX has been the topic of several research analyst reports. HC Wainwright decreased their target price on shares of REGENXBIO from $36.00 to $34.00 and set a “buy” rating on the stock in a research report on Monday, March 17th. Raymond James initiated coverage on shares of REGENXBIO in a research note on Friday, February 7th. They set an “outperform” rating and a $27.00 price objective for the company. Chardan Capital restated a “buy” rating and set a $52.00 price objective on shares of REGENXBIO in a report on Thursday, March 20th. Morgan Stanley lifted their target price on REGENXBIO from $22.00 to $24.00 and gave the company an “overweight” rating in a report on Friday, March 14th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $30.00 price target on shares of REGENXBIO in a research note on Tuesday, January 21st. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.78.

REGENXBIO Trading Up 4.3 %

RGNX opened at $7.05 on Thursday. REGENXBIO Inc. has a twelve month low of $5.62 and a twelve month high of $20.77. The firm has a market cap of $353.11 million, a price-to-earnings ratio of -1.40 and a beta of 1.26. The company has a fifty day simple moving average of $7.36 and a 200 day simple moving average of $8.65.

REGENXBIO (NASDAQ:RGNX) last announced its earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.27) by $0.26. The company had revenue of $21.21 million during the quarter, compared to the consensus estimate of $23.70 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. On average, analysts forecast that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.